SG10201703682YA - Inhibitors of histone demethylases - Google Patents
Inhibitors of histone demethylasesInfo
- Publication number
- SG10201703682YA SG10201703682YA SG10201703682YA SG10201703682YA SG10201703682YA SG 10201703682Y A SG10201703682Y A SG 10201703682YA SG 10201703682Y A SG10201703682Y A SG 10201703682YA SG 10201703682Y A SG10201703682Y A SG 10201703682YA SG 10201703682Y A SG10201703682Y A SG 10201703682YA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- histone demethylases
- demethylases
- histone
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title 1
- 108010074870 Histone Demethylases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708806P | 2012-10-02 | 2012-10-02 | |
| DKPA201200599 | 2012-10-02 | ||
| US201361770050P | 2013-02-27 | 2013-02-27 | |
| DKPA201370112 | 2013-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201703682YA true SG10201703682YA (en) | 2017-06-29 |
Family
ID=52781382
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201703682YA SG10201703682YA (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
| SG11201502452RA SG11201502452RA (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502452RA SG11201502452RA (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US20150203453A1 (es) |
| EP (3) | EP3023415B1 (es) |
| JP (2) | JP6530313B2 (es) |
| KR (1) | KR102160320B1 (es) |
| CN (2) | CN107434803B (es) |
| AP (1) | AP2015008389A0 (es) |
| AU (1) | AU2018200876C1 (es) |
| BR (1) | BR112015007083A2 (es) |
| CA (2) | CA3095019C (es) |
| CL (1) | CL2015000829A1 (es) |
| CR (1) | CR20150217A (es) |
| CY (1) | CY1118695T1 (es) |
| DK (1) | DK2903968T3 (es) |
| EA (1) | EA030698B1 (es) |
| ES (2) | ES2654143T3 (es) |
| HK (1) | HK1215710A1 (es) |
| HR (1) | HRP20170358T1 (es) |
| HU (1) | HUE033380T2 (es) |
| IL (2) | IL237831A (es) |
| LT (1) | LT2903968T (es) |
| MD (1) | MD20150043A2 (es) |
| ME (1) | ME02597B (es) |
| MX (1) | MX2015003959A (es) |
| NZ (1) | NZ706635A (es) |
| PE (1) | PE20150998A1 (es) |
| PH (2) | PH12015500730A1 (es) |
| PL (2) | PL3023415T3 (es) |
| PT (2) | PT2903968T (es) |
| RS (1) | RS55764B1 (es) |
| SG (2) | SG10201703682YA (es) |
| SI (2) | SI2903968T1 (es) |
| SM (2) | SMT201700109T1 (es) |
| WO (1) | WO2014053491A1 (es) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20150998A1 (es) | 2012-10-02 | 2015-06-29 | Epitherapeutics Aps | Inhibidores de histona demetilasas |
| PL2961736T3 (pl) * | 2013-02-27 | 2018-08-31 | Gilead Sciences, Inc. | Inhibitory demetylaz histonowych |
| AR099890A1 (es) * | 2014-03-31 | 2016-08-24 | Epitherapeutics Aps | Inhibidores de histona demetilasas |
| MA40470A (fr) | 2014-08-27 | 2016-03-03 | Gilead Sciences Inc | Composés et procédés d'inhibition des histones déméthylases |
| JP6723663B2 (ja) * | 2014-09-17 | 2020-07-15 | ă»ă«ăžăŒăł ăŻăȘăłăăŁă»ă« ăȘă”ăŒăïŒă€ăłăŻïŒ | ăăčăăłăăĄăă©ăŒăŒé»ćźłć€ |
| EP3453710B1 (en) | 2014-09-17 | 2022-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| MX2017005346A (es) | 2014-10-29 | 2017-08-02 | Dong A St Co Ltd | Nuevos compuestos de piridopirimidinona para modular la actividad catalitica de histona lisina desmetilasas (kdm). |
| US20190100769A1 (en) * | 2014-10-31 | 2019-04-04 | Massachusetts Institute Of Technology | Massively parallel combinatorial genetics for crispr |
| AU2016250099A1 (en) * | 2015-04-14 | 2017-10-12 | Gilead Sciences, Inc. | Methods of treating hepatitis B virus |
| US10206930B2 (en) * | 2015-08-14 | 2019-02-19 | New York University | Methods for treating T-cell acute lymphoblastic leukemia |
| WO2017099829A1 (en) | 2015-12-11 | 2017-06-15 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
| JP6883913B2 (ja) | 2015-12-28 | 2021-06-09 | ă»ă«ăžăŒăł ăŻăȘăłăăŁă»ă« ăȘă”ăŒăïŒă€ăłăŻïŒ | ăăčăăłăăĄăă©ăŒăŒé»ćźłć€ |
| JP6970681B2 (ja) * | 2016-03-15 | 2021-11-24 | ă»ă«ăžăŒăł ăŻăȘăłăăŁă»ă« ăȘă”ăŒăïŒă€ăłăŻïŒ | ăăčăăłăăĄăă©ăŒăŒé»ćźłć€ |
| WO2017198785A1 (en) * | 2016-05-18 | 2017-11-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Oxime derivatives useful as inhibitors of histone demethylase kdm4c |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | ĐжОлОЎ ĐĄĐ°ĐčŃĐœŃ, ĐĐœĐș. | ĐĄĐżĐŸŃĐŸĐ±Ń Đ»Đ”ŃĐ”ĐœĐžŃ ĐžĐœŃĐ”ĐșŃĐžĐč, ĐČŃĐ·ŃĐČĐ°Đ”ĐŒŃŃ ĐČĐžŃŃŃĐŸĐŒ гДпаŃĐžŃĐ° b |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | Ù Ű±ÙۚۧŰȘ ŰšÙ۱ÙÙÙŰČÙÙ ŰšÙۧ ۧ۳ŰȘŰšŰŻŰ§Ù Ùۧ۳ŰȘŰźŰŻŰ§Ù Ű§ŰȘÙۧ |
| JP6746776B2 (ja) | 2016-09-02 | 2020-08-26 | ăźăȘăąăŒă ă”ă€ăšăłă·ăŒășïŒ ă€ăłăłăŒăăŹă€ăăă | ïœïœïœæ§ććźčäœèȘżçŻć€ććç© |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| IL308894A (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | çŸććșć©ç§ćžèĄä»œæéć Źćž | æżè«ŸçŠéćæé èș(tenofovir alafenamide)äčæ¶ć |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | Ù Ű±ÙۚۧŰȘ ÙŰčÙۧۏ ۄ۔ۧۚ۩ ŰšŰčŰŻÙÙ ÙÙ۱ÙŰł ۧÙۧÙŰȘÙۧۚ ۧÙÙŰšŰŻÙ b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Ù Ű«ŰšŰ·Ű§ŰȘ pd-1/pd-l1 |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| MY196582A (en) | 2018-02-13 | 2023-04-19 | Gilead Sciences Inc | PD-1/PD-L1 Inhibitors |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | êžžëŠŹì ë ìŹìŽìžììŠ, ìžìœíŹë ìŽí°ë | Hbv ëł”ì ì”ì ì ëĄìì ìčíë íŒëĄ€ëŠŹì§ íí©ëŹŒ |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | æ·ć ç§ćžéąææ©ććžèçç©ććžç 究æ | 3'3'-ç°äșæ žè·é ž |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | æ·ć ç§ćžéąææ©ććžèçç©ććžç 究æ | 2'3'-ç°äșæ žè·é ž |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | æ·ć ç§ćžéąææ©ććžèçç©ććžç 究æ | ïŒïŒïŒïŒâç°äșæ žè·é ž |
| CN108464984A (zh) * | 2018-04-09 | 2018-08-31 | ćŸć·ç»Žćș·çç©ç§ææéć Źćž | äžç§æČ»çéȘšèç€çèĄšè§éäŒ èŻç© |
| CN108186643B (zh) * | 2018-04-09 | 2021-04-20 | ćŸć·ç»Žćș·çç©ç§ææéć Źćž | äžç§ć ·æććæéȘšèç€ćæçèŻç©ç»ćç©ćć ¶ćșçš |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | çŸćçČŸćŻçç©ç§ćžć Źćž | ć°bćèçç æŻćșć é«äžäčèć„ćșćć ·æçčç°æ§äčæäœłćäčç¶ć·„çšćć·šæ žé žé ¶ |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | æ·ć ç§ćžéąææ©ććžèçç©ććžç 究æ | ć ć«çąłç°æ žè·é žäč2â3âïŒç°äșæ žè·é ž |
| CN108530381B (zh) * | 2018-05-07 | 2021-09-21 | äžæ”·ç§æć€§ćŠ | äžç§ç±é °èșé Żć¶ć€äșèșèĄçç©çæčæł |
| EP3813863A4 (en) | 2018-06-28 | 2022-07-06 | Dana Farber Cancer Institute, Inc. | TARGETING OF MULTIPLE ANTIGENS WITH MULTIPLEX CAR-T CELLS IN SOLID AND LIQUID MALIGNOS |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020033377A1 (en) * | 2018-08-06 | 2020-02-13 | Dana-Farber Cancer Institute, Inc. | Histone demethylase 5 inhibitors and uses thereof |
| CN109234313A (zh) * | 2018-09-25 | 2019-01-18 | äžæ”·äș€é性ćŠć»ćŠéąéć±çŹŹäčäșșæ°ć»éą | ć ±èœŹæ蜜äœćć ¶ćšæéȘšèç€èŻç©äžçćșçš |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| PL3873903T3 (pl) | 2018-10-31 | 2024-05-20 | Gilead Sciences, Inc. | Podstawione zwiÄ zki 6-azabenzimidazolu jako inhibitory hpk1 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | æ·ć ć ±ććœææșććŠäžçç©ććŠç 究æ | 2â3â-çŻäșæ žè·é žćć ¶ćèŻ |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | çŸććșć©ç§ćžèĄä»œæéć Źćž | éĄéžćé«èȘżçŻćäčćșé«ćœąćŒ |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | çŸććșć©ç§ćžèĄä»œæéć Źćž | éĄéžćé«èȘżçŻćäčćșé«ćœąćŒ |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US20210009718A1 (en) | 2019-06-25 | 2021-01-14 | Gilead Sciences, Inc. | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| CN110652589A (zh) * | 2019-10-12 | 2020-01-07 | äžćœäșșæ°è§ŁæŸćéććć»ć€§ćŠ | Gasc1æć¶ććšć¶ć€æČ»çèççèŻç©äžçćșçš |
| EP4567109A3 (en) | 2019-12-06 | 2025-09-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN111073900B (zh) * | 2019-12-09 | 2023-05-02 | æž©æ°éŁćéćąèĄä»œæéć Źćž | äžç§æé«çȘć éèèćèČæççæčæł |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | çŸććșć©ç§ćžèĄä»œæéć Źćž | 4â-c-ç¶ć代-2-éč”ćș-2â-ć»æ°§è șè·æ žè·äčćè„ćć ¶èŁœé èäœżçšæčæł |
| EP4159846A4 (en) | 2020-05-26 | 2024-08-14 | Healios K.K. | HYPOIMMUNOGENIC CELLS |
| WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| CN111905102A (zh) * | 2020-09-04 | 2020-11-10 | çŠć»șć»ç§ć€§ćŠéć±çŹŹäžć»éą | Ezh2æć¶ććšæČ»çè¶èŽšç€äžçćșçš |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | çŸććșć©ç§ćžèĄä»œæéć Źćž | ä»çœçŽ 2-Fcèćèçœćäœżçšæčæł |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN114907317B (zh) * | 2022-06-01 | 2023-06-13 | éć·ć€§ćŠ | äžç§ćĄć-äčçŻćș-ćŒçé žèĄçç©ćć ¶ć¶ć€æčæłććșçš |
| CN115806522B (zh) * | 2022-11-24 | 2025-05-13 | äžćœèŻç§ć€§ćŠ | äžç§ć代ćĄć¶èĄçç©ćć ¶ćșçš |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| GB8717374D0 (en) | 1987-07-22 | 1987-08-26 | Smith Kline French Lab | Pharmaceutically active compounds |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ăăă«ăăŁăč ăąăŻăăšăłăČăŒă«ă·ăŁăă | ăšăă·ăăłăźèŁœé æłăăăłèŁœé éçšäžă«ćŸăăăäžéççŁç© |
| DE69724269T2 (de) | 1996-09-06 | 2004-06-09 | Obducat Ab | Verfahren fĂŒr das anisotrope Ă€tzen von strukturen in leitende materialien |
| US5874438A (en) | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
| AU753546B2 (en) | 1996-11-18 | 2002-10-24 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| NZ506742A (en) | 1998-02-25 | 2003-09-26 | Sloan Kettering Inst Cancer | Synthesis of desoxyepothilones and hydroxy acid derivative intermediates |
| IL143069A0 (en) | 1998-11-20 | 2002-04-21 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6620811B2 (en) | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| MXPA04008893A (es) | 2002-03-13 | 2005-06-20 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilados como inhibidores de mek. |
| JP2008503469A (ja) | 2004-06-17 | 2008-02-07 | ăŻă€ăč | ăŽăăăăăăłæŸćșăă«ăąăłććźčäœăąăłăżăŽăăčă |
| WO2008002671A2 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| JPWO2009119088A1 (ja) * | 2008-03-25 | 2011-07-21 | æŠç°èŹćć·„æ„æ ȘćŒäŒç€Ÿ | è€çŽ ç°ććç© |
| SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | ŰȘ۱ÙÙۚ۩ Ű”ÙŰŻÙۧÙÙŰ© ŰŹŰŻÙŰŻŰ© Ù Ű¶Ű§ŰŻŰ© ÙÙŰłŰ±Ű·Ű§Ù |
| RU2011121655A (ru) * | 2008-10-29 | 2012-12-10 | ĐĄĐ”ŃŃŃĐžŃ Đ€Đ°ŃĐŒĐ°ŃŃŃŃĐžĐșалз, ĐĐœĐș. | ĐŃĐŸĐžĐ·ĐČĐŸĐŽĐœŃĐ” пОŃĐžĐŽĐžĐœĐ°, бОŃĐžĐșлОŃĐ”ŃĐșОД ĐżŃĐŸĐžĐ·ĐČĐŸĐŽĐœŃĐ” пОŃĐžĐŽĐžĐœĐ° Đž ŃĐŸĐŽŃŃĐČĐ”ĐœĐœŃĐ” Đ°ĐœĐ°Đ»ĐŸĐłĐž ĐČ ĐșĐ°ŃĐ”ŃŃĐČĐ” ĐŒĐŸĐŽŃĐ»ŃŃĐŸŃĐŸĐČ ŃĐžŃŃŃĐžĐœĐ° |
| AU2010279359A1 (en) | 2009-08-07 | 2012-02-16 | The Wistar Institute | Compositions containing JARID1B inhibitors and methods for treating cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | ĐĐ°ŃŃĐŸŃŃĐČĐ°ĐœĐœŃ c-met-ĐŒĐŸĐŽŃĐ»ŃŃĐŸŃŃĐČ ĐČ ĐșĐŸĐŒĐ±ŃĐœĐ°ŃŃŃ Đ· ŃĐ”ĐŒĐŸĐ·ĐŸĐ»ĐŸĐŒŃĐŽĐŸĐŒ ŃĐ°/Đ°Đ±ĐŸ ĐżŃĐŸĐŒĐ”ĐœĐ”ĐČĐŸŃ ŃĐ”ŃĐ°ĐżŃŃŃ ĐŽĐ»Ń Đ»ŃĐșŃĐČĐ°ĐœĐœŃ ŃĐ°ĐșŃ | |
| PE20130038A1 (es) | 2010-03-10 | 2013-01-28 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de jak1 |
| JP5841529B2 (ja) * | 2010-05-27 | 2016-01-13 | ăăăèŁœèŹæ ȘćŒäŒç€Ÿ | è€çŽ ç°ććç©ćăłïœïŒććźčäœæźæć€ |
| WO2012007007A1 (en) * | 2010-07-15 | 2012-01-19 | Epitherapeutics Aps | Inhibitors of hdme |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| PH12013501871A1 (en) | 2011-03-25 | 2019-06-03 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
| SG2014009609A (en) | 2011-08-15 | 2014-05-29 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
| PL2772490T3 (pl) | 2011-10-27 | 2016-11-30 | Aminoalkilo-podstawiona pochodna n-tienylobenzamidu | |
| WO2013081091A1 (ja) * | 2011-12-01 | 2013-06-06 | ćœç«ć€§ćŠæłäșș ćèć€§ćŠ | éçčç°çè éç©ăäœæžăăăæŸć°æ§æšèăăȘăăăăäœèŁœçšèŹć€ |
| CN102585150B (zh) * | 2012-02-01 | 2013-09-04 | ćć ŽćŠéą | ç»ç©æ¶é„°çšéŽçŠ»ćæ°Žæ§èæ°šé ŻćæŁäœçć¶ć€æčæł |
| WO2013123411A1 (en) | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
| WO2013129435A1 (ja) * | 2012-02-28 | 2013-09-06 | ććçșé ”ăăȘăłæ ȘćŒäŒç€Ÿ | çžźç°ăăȘăă§ăłèȘć°äœ |
| PE20150998A1 (es) | 2012-10-02 | 2015-06-29 | Epitherapeutics Aps | Inhibidores de histona demetilasas |
| MX2015007205A (es) | 2012-12-06 | 2016-03-31 | Quanticel Pharmaceuticals Inc | Inhibidores de la desmetilasa de histona. |
| US9617242B2 (en) | 2012-12-19 | 2017-04-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EA028774B1 (ru) | 2012-12-21 | 2017-12-29 | ĐĐČĐŸĐœŃĐžŃДл ЀаŃĐŒĐ°ŃŃŃŃĐžĐșĐ°Đ»Ń, ĐĐœĐș. | ĐĐœĐłĐžĐ±ĐžŃĐŸŃŃ ĐłĐžŃŃĐŸĐœĐŽĐ”ĐŒĐ”ŃĐžĐ»Đ°Đ·Ń |
| PL2961736T3 (pl) | 2013-02-27 | 2018-08-31 | Gilead Sciences, Inc. | Inhibitory demetylaz histonowych |
| HRP20171609T1 (hr) | 2013-03-15 | 2017-12-15 | Quanticel Pharmaceuticals Inc | Inhibitori histon demetilaze |
| CA2922925A1 (en) | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Antiproliferative compounds |
| AR099890A1 (es) | 2014-03-31 | 2016-08-24 | Epitherapeutics Aps | Inhibidores de histona demetilasas |
-
2013
- 2013-10-01 PE PE2015000454A patent/PE20150998A1/es not_active Application Discontinuation
- 2013-10-01 MD MDA20150043A patent/MD20150043A2/ro not_active Application Discontinuation
- 2013-10-01 PT PT137709283T patent/PT2903968T/pt unknown
- 2013-10-01 SG SG10201703682YA patent/SG10201703682YA/en unknown
- 2013-10-01 SG SG11201502452RA patent/SG11201502452RA/en unknown
- 2013-10-01 AP AP2015008389A patent/AP2015008389A0/xx unknown
- 2013-10-01 HR HRP20170358TT patent/HRP20170358T1/hr unknown
- 2013-10-01 ES ES15200672.2T patent/ES2654143T3/es active Active
- 2013-10-01 EP EP15200672.2A patent/EP3023415B1/en active Active
- 2013-10-01 CN CN201710513194.9A patent/CN107434803B/zh active Active
- 2013-10-01 WO PCT/EP2013/070457 patent/WO2014053491A1/en not_active Ceased
- 2013-10-01 BR BR112015007083A patent/BR112015007083A2/pt active Search and Examination
- 2013-10-01 RS RS20170216A patent/RS55764B1/sr unknown
- 2013-10-01 ME MEP-2017-46A patent/ME02597B/me unknown
- 2013-10-01 SI SI201330511A patent/SI2903968T1/sl unknown
- 2013-10-01 CA CA3095019A patent/CA3095019C/en active Active
- 2013-10-01 CA CA2885969A patent/CA2885969C/en active Active
- 2013-10-01 US US14/381,558 patent/US20150203453A1/en active Granted
- 2013-10-01 HU HUE13770928A patent/HUE033380T2/en unknown
- 2013-10-01 EP EP16186022.6A patent/EP3150582A1/en not_active Withdrawn
- 2013-10-01 EA EA201500394A patent/EA030698B1/ru not_active IP Right Cessation
- 2013-10-01 CN CN201380059974.0A patent/CN104981458B/zh active Active
- 2013-10-01 NZ NZ706635A patent/NZ706635A/en not_active IP Right Cessation
- 2013-10-01 LT LTEP13770928.3T patent/LT2903968T/lt unknown
- 2013-10-01 MX MX2015003959A patent/MX2015003959A/es unknown
- 2013-10-01 PL PL15200672T patent/PL3023415T3/pl unknown
- 2013-10-01 PT PT152006722T patent/PT3023415T/pt unknown
- 2013-10-01 PL PL13770928T patent/PL2903968T3/pl unknown
- 2013-10-01 JP JP2015534985A patent/JP6530313B2/ja active Active
- 2013-10-01 HK HK16103714.1A patent/HK1215710A1/zh unknown
- 2013-10-01 KR KR1020157011211A patent/KR102160320B1/ko active Active
- 2013-10-01 SM SM20170109T patent/SMT201700109T1/it unknown
- 2013-10-01 ES ES13770928.3T patent/ES2617905T3/es active Active
- 2013-10-01 EP EP13770928.3A patent/EP2903968B1/en active Active
- 2013-10-01 DK DK13770928.3T patent/DK2903968T3/en active
- 2013-10-01 SI SI201330878T patent/SI3023415T1/en unknown
-
2014
- 2014-08-28 US US14/472,059 patent/US10189787B2/en active Active
-
2015
- 2015-03-19 IL IL237831A patent/IL237831A/en not_active IP Right Cessation
- 2015-04-01 PH PH12015500730A patent/PH12015500730A1/en unknown
- 2015-04-01 CL CL2015000829A patent/CL2015000829A1/es unknown
- 2015-04-28 CR CR20150217A patent/CR20150217A/es unknown
-
2017
- 2017-02-16 SM SM201700109T patent/SMT201700109B/it unknown
- 2017-02-17 US US15/436,055 patent/US10221139B2/en active Active
- 2017-03-07 CY CY20171100297T patent/CY1118695T1/el unknown
- 2017-07-02 IL IL253259A patent/IL253259B/en not_active IP Right Cessation
- 2017-07-19 PH PH12017501306A patent/PH12017501306A1/en unknown
- 2017-11-07 JP JP2017214526A patent/JP2018016661A/ja active Pending
-
2018
- 2018-02-06 AU AU2018200876A patent/AU2018200876C1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253259A0 (en) | Inhibitors of histone demethylases | |
| IL240439A0 (en) | Inhibitors of histone demethylases | |
| ZA201505007B (en) | Histone demethylase inhibitors | |
| PL2934145T3 (pl) | Inhibitory demetylazy histonowej | |
| AP4029A (en) | Inhibitors of beta-secretase | |
| ZA201504294B (en) | Heterocyclic glutaminase inhibitors | |
| PT2680694T (pt) | Inibidores de histona deacetilase | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| IL236963A0 (en) | beta-secretase inhibitors | |
| PL2888228T3 (pl) | Inhibitory oddziaĆywania CD40-TRAF6 | |
| AU2013326554A1 (en) | Inhibitors of histone demethylases | |
| PT2961736T (pt) | Inibidores de histona desmetilases |